Mark D. Ewalt has received speaking fees from Pillar Biosciences. Paul Hamlin has consulted for ADC Therapeutics. JL has consulted for OncLive, Merck. Steven M. Horwitz has consulted for Abcuro, Inc., Arvinas, Autolus, Auxilus Pharma, BlueSphere Bio, Corvus, Daiichi Sankyo, DrenBio, J&J Medicine/Janssen Research & Development, Kyowa Hakko Kirin, March Bio, ONO Pharmaceuticals, Pfizer, SecuraBio, Shoreline Biosciences, Inc., SymBio, Takeda and Yingli Pharma Limited. Has received research funding from ADC Therapeutics, Affimed, Aileron, Celgene, Corvus, Crispr Therapeutics, Daiichi Sankyo, Forty Seven, Inc., Kyowa Hakko Kirin, Takeda, Seattle Genetics, Trillium Therapeutics, Treeline and SecuraBio. Erel Joffe has received honoraria from J&J, abbvie. Anita Kumar has received research funding from Celgene, Seattle Genetics, Adaptive Biotechnologies, Genentech, Abbvie Pharmaceuticals, Loxo/Lily Oncology, Astra Zeneca, Pharmacyclics, Beigene; is a current equity holder in publicly-traded company for BridgeBio; has consulted for Astra Zeneca, Loxo/Lily Oncology, Janssen, Genentech, Kite Pharma. Alison J. Moskowitz has received honoraria from Merck, Seattle Genetics; has received research funding from Bristol-Myers Squibb, Merck, Seattle Genetics, Beigene, Incyte, ADC Therapeutics. Ariela Noy received research funding from Rafael Pharma and Pharmacyclics; has consulted for Pharmacyclics, Medscape, Targeted Oncology, Morphosys, Pharmacyclics and Janssen; received research funding from NIH. Maria L. Palomba has received honoraria from Smart Immune, Cellectar, Seres Therapeutics, Rheos, Juno, Ceramedix, Pluto Immunotherapeutics, Novartis, Garuda Therapeutics, MustangBio, Thymofox, Kite, BMS, Synthekine. Andrew D. Zelenetz has received honoraria from AstraZeneca, Janssen Pharmaceuticals, F. Hoffmann-La Roche Ltd, Pharmacyclics, Gilead, BMS, MEI Pharma Inc; has consulted for AstraZeneca, F. Hoffmann-La Roche Ltd, Janssen Pharmaceuticals, Pharmacyclics, Gilead, BeiGene, BMS, MEI Pharma Inc; has received research funding from Abbvie, F. Hoffmann-La Roche Ltd, Gilead, MEI Pharma Inc; has membership on an entity’s Board of Directors or advisory committees for Lymphoma Research Foundation. Ahmet Dogan has consulted for Seattle Genetics, Takeda, EUSA Pharma, AbbVie, Peerview, Physicans’ Education Resource; has received fundings from Roche/Genentech. Klaus J. Busam has Royalties for textbook published by Elsevier. Gilles Salles has received financial compensations for participating in advisory boards or Data Monitoring Committees: Abbvie, Beigene, BMS, Foresight, Genentech/Roche, Genmab, Janssen, Ipsen Kite/Gilead, Lilly, Merck, Novartis, Pfizer, SERB pharmaceuticals; has received financial compensations for consulting from: Abbvie, Ellipses, Genentech/Roche, Genmab, Incyte, Kite/Gilead; has received research support from Abbvie, Genentech, Genmab Janssen, Ipsen, which was managed by his institution. Matthew J. Matasar has received honoraria from ADC Therapeutics, AstraZeneca, Bayer, BMS, Celgene, Epizyme, IMV Therapeutics, J&J, Kite, Regeneron, Roche, Pfzier; has consulted for Bayer, Genetech, Kite, Roche, Seattle Genetics; has received research funding from Seattle Genetics, Roche, Pharmacyclics, Genentech, J&J, Bayer. Lorenzo Falchi has received research funding from Roche, Genentech, Genmab, AbbVie, Innate Pharma, Beigene, Astrazeneca; has consulted for Roche, Genentech, Genmab, AbbVie, Sanofi, Evolveimmune, Astrazeneca, Merck; was in advisory board of AbbVie, Genentech, ADC therapeutics, Seagen, Ipsen, Johnson & Johnson; received honoraria from Roche, Genmab, AbbVie, Kite; received travel support from Genmab, AbbVie, Roche, Kite. All other authors have no COI.